Articles tagged "Kidney transplantation"

2022 American Transplant Congress
The Financial Burden Of Transplant – A Commercial Claims Analysis
G. Katz-Greenberg¹, O. Osazuwa-Peters¹, J. Gonzalez¹, S. Sanoff¹, O. Oloruntoba¹, N. Chan¹, E. J. Gordon², C. Scales¹, A. Brookhart¹, L. McElroy¹
¹Duke University, Durham, NC, ²Surgery, Northwestern University Feinberg School of Medicine, OAK PARK, IL
*Purpose: Despite access to health insurance, financial concerns are among the most prevalent patient-reported barriers to kidney and liver transplantation (KT and LT, respectively). We…
2022 American Transplant Congress
Donor-Derived Cell-Free DNA (dd-cfDNA) for Assessment of Response After Treatment of Allograft Rejection
R. Gohh¹, J. Klein², M. Jagadeesan³, V. Rao⁴, M. Weir⁵, H. Gilligan⁶, G. Shekhtman⁷, N. Agrawal⁸, Y. Fu⁹, E. Akalin¹⁰
¹Alpert School of Medicine, Brown University, Providence, RI, ²University of Kansas Medical Center, Kansas City, KS, ³George Washington School of Medicine, Washington, DC, ⁴Medical University of South Carolina, Charleston, SC, ⁵University of Maryland, Baltimore, MD, ⁶Massachusetts General Hospital, Boston, MA, ⁷CareDx Inc., Brisbane, CA, ⁸CareDx Inc, Brisbane, CA, ⁹CareDx, Brisbane, CA, ¹⁰Montefiore Medical Center, Bronx, NY
*Purpose: Surveillance of dd-cfDNA after therapy for rejection represents a promising strategy for monitoring post-treatment response. We assessed post-rejection kinetics of dd-cfDNA among kidney transplant…
2022 American Transplant Congress
Can dd-cf DNA Eliminate Unnecessary Biopsies? The Answer is Yes!
K. Andreoni, Y. Chalicheemala, M. Debroy, M. Maklad, K. Zhao, M. Aeder, A. Jittirat, D. Ecabert, A. Bixby, C. Burrelli, K. Chavin
University Hospitals Cleveland Medical Center, Cleveland, OH
*Purpose: Historically our center has been one that routinely performs biopsies. We perform them pre-perfusion, for slowly recovering allografts between day 10-14, and routinely at…
2022 American Transplant Congress
Monitoring of Kidney Allograft Rejection Using Patient-Centric State-of-the-Art Tools – An Approach to Early Diagnosis and Intervention
A. Rizvi¹, A. Gamilla-Crudo², S. A. Hussain³, M. Kueht⁴, J. Fair⁴, M. Mujtaba²
¹Internal Medicine, Nephrology, University of Texas Medical Branch, Galveston, TX, ²University of Texas Medical Branch, Galveston, TX, ³Nephrology, University of Texas Medical Branch, Houston, TX, ⁴Surgery, University of Texas Medical Branch, Galveston, TX
*Purpose: The early detection and timely management of kidney allograft rejection using traditional markers including serum creatinine (SCr) has been inadequate due to lagging response.…
2022 American Transplant Congress
Findings from Pharmacist-Performed Medication Adherence Assessments in Living Donor Kidney Transplant Candidates and Missed Medication Rates Early After Transplant
L. Nguyen¹, R. Samudralwar², A. Forte², G. Malat², C. Christopher¹, J. Rivera¹, T. Ilori¹, X. Liu¹, J. Trofe-Clark²
¹Pharmacy, Hosp of Univ of Pennsylvania, Philadelphia, PA, ²Penn Transplant Institute and Pharmacy Dept, Hosp of Univ of Pennsylvania, Philadelphia, PA
*Purpose: Evaluation and monitoring for medication non-adherence (NA) is necessary pre- and post-kidney transplant (KTx) to optimize outcomes. This study aims to describe findings post-implementation…
2022 American Transplant Congress
Disparities Associated with Road Travel Distance of Living Kidney Donors in the United States: An SRTR Analysis
K. Nijhar¹, A. Kernodle¹, J. D. Motter¹, K. Khoo¹, A. Massie², E. King³, D. Segev¹
¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins School of Medicine, Baltimore, MD, ³Johns Hopkins Hospital, Baltimore, MD
*Purpose: To identify disparities associated with travel distance of living kidney donors (LKDs) in the United States.*Methods: We identified all U.S. citizen adult LKDs from…
2022 American Transplant Congress
PCR-Enhanced Performance Characteristics of TruGraf Gene Expression Profile in Kidney Transplant
P. West-Thielke¹, J. Fleming¹, C. Miller¹, N. Grund¹, A. Sutton¹, R. Sinha², M. Miller², S. Kleiboeker², J. Weems³
¹Transplant Genomics, Inc., Framingham, MA, ²Eurofins-Viracor, Lees Summit, MO, ³Transplant Genomics, Inc., Lees Summit, MO
*Purpose: The aim of this study was to perform clinical validation of TruGraf GEP using PCR methodology, as compared to the previously used microarray methodology,…
2022 American Transplant Congress
Clinical Utility of Donor-Derived Cell-Free DNA During the Period of Recovery of Renal Function After Kidney Transplantation
Y. C. Dreige¹, G. Bittencourt Pereira Lima¹, M. Cristelli¹, M. Nakamura¹, R. D. Foresto¹, P. Pierry¹, R. Ponsirenas², J. Levi¹, J. Medina¹, H. Tedesco¹
¹Hospital do Rim, Universidade Federal de São Paulo, São Paulo, Brazil, ²Medical Affairs, CareDx, Miami, FL
*Purpose: This study evaluates the clinical utility of monitoring donor-derived cell-free DNA (dd-cfDNA), a biomarker of kidney injury, in recipients of high Kidney Donor Profile…
2022 American Transplant Congress
COVID-19 Vaccination Induces a Poor Interleukin-21 Memory T-cell Response in Kidney Transplant Recipients
S. R. Malahe¹, Y. den Hartog¹, R. de Kuiper¹, D. Reijerkerk¹, D. Geers², C. H. GeurtsvanKessel², M. M. Kho¹, R. D. de Vries², M. E. Reinders¹, C. C. Baan¹
¹Internal Medicine, Nephrology and Transplantation, Erasmus MC, Rotterdam, Netherlands, ²Viroscience, Erasmus MC, Rotterdam, Netherlands
*Purpose: COVID-19-related morbidity and mortality is high among kidney patients. Several studies recently suggested low humoral and cellular immune responses after two doses of mRNA-1273…
2022 American Transplant Congress
De Novo DSA in the Setting of Stable Allograft Function is a Benign Finding
R. J. Knight, E. A. Graviss, D. T. Nguyen, T. N. Eagar, S. G. Yi, H. Podder, M. Hobeika, R. McMillan, A. O. Gaber
Houston Methodist Hospital, Houston, TX
*Purpose: We sought to determine the long-term outcome of renal allografts that developed de novo DSA (dnDSA) in the setting of stable renal function.*Methods: A…